Skip to content Skip to footer
Subscribe Now
Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots:At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701PThe study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701PBiocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025

Read more

ThoughtSpot_Andrea Lacey
THOUGHTSPOT

The Role of Artificial Intelligence in Revolutionizing Eye Surgery

Artificial intelligence (AI) is rapidly transforming ophthalmology, bringing unprecedented precision and safety to eye surgeries. The integration of AI-driven technologies into procedures like LASIK and cataract surgery is revolutionizing patient outcomes, reducing complications, and setting new standards in vision correction. Advancements in machine learning and surgical robotics enable ophthalmologists to perform complex operations with enhanced…
December 13, 2024

Read more

VIEWPOINTS_Sujay Jadhav_2023
VIEWPOINTS

Sujay Jadhav converses about VeraSite, a recently launched subscription-based tool for clinical trial site selection

Shots: In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection  To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData  Currently available in the…
October 17, 2023

Read more

VIEWPOINTS_Dr. Jeff Cleland_2023
VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots:Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DMEJeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DMEThe interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023

Read more

Viewpoints_Patrick Mooney
VIEWPOINTS

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Shots:Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertensionPatrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trialThe interview gives an understanding of Spyglass’…
November 29, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]